Leap Therapeutics To Present at 19th Annual BIO CEO & Investor Conference
February 09, 2017 09:12 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Douglas...
Leap Therapeutics Presents Biomarker and Efficacy Data at the Cholangiocarcinoma Foundation 2017 Annual Meeting
February 03, 2017 08:00 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, announced the presentation of...
Leap Therapeutics and Macrocure Complete Merger Transaction
January 23, 2017 09:15 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced the...
Leap Therapeutics Presents Biomarker Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer
January 19, 2017 15:30 ET
|
Leap Therapeutics
Durable responses observed in patients with Wnt-pathway genetic mutations CAMBRIDGE, Mass., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. reported updated clinical and biomarker data...